GlassScriptPhysician profile
Laura Leigh Younce
NPI 1407854540
$8,863.34
in general payments reported to CMS, 2019-2025
22 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $641 · 2021: $1,021 · 2022: $1,678 · 2023: $1,521 · 2024: $1,883 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,471.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,895.58 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,340.96 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $973.59 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $951.92 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $490.00 | 2019-2025 | Watchman Flx, Watchman Access System |
| Scpharmaceuticals INC. | $463.11 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.46 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $393.69 | 2020-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $305.75 | 2019-2025 | Wainua, Farxiga, Andexxa |
| Kestra Medical Technology Services, INC. | $288.46 | 2023-2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $253.51 | 2019-2021 | |
| Heartflow, INC. | $198.76 | 2023-2025 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $195.61 | 2022-2025 | |
| Abbott Laboratories | $186.67 | 2021-2023 | Mitraclip |
| Pfizer INC. | $171.38 | 2019-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $128.15 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $59.60 | 2022-2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $47.24 | 2021-2025 | |
| Masimo Corporation | $42.18 | 2025 | Sedline |
| Vital Connect, INC | $30.26 | 2024 | Vitalpatch Rtm |
| Csl Behring | $17.95 | 2019 | |
| Gilead Sciences, INC. | $15.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Younce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.